A股異動 | 聯泓新科跌6% 前三季淨利減少5.38%
格隆匯10月17日丨聯泓新科(003022.SZ)跌6.81%,報35.86元,總市值479億元。公司16日公吿顯示,公司前三季度營業收入6,416,879,632.66元,同比增加13.25%,歸屬上市公司股東的淨利潤777,790,152.80元,同比減少5.38%。其中2022年第三季度,公司單季度主營收入24.79億元,同比上升34.72%;單季度歸母淨利潤3.21億元,同比上升14.32%。公吿稱,公司前三季度累計淨利潤略有下降主要因為一季度實施了EVA裝置技術升級擴能改造,及進行碳酸酯裝置、超高分子量聚乙烯裝置與公用工程系統連接施工和檢修,EVA裝置停車28天,其他相關裝置同步停車7-15天。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.